Ulteriori informazioni
"According to longstanding scientific consensus, vaccines are widely regarded as playing a fundamental role in public health. Therefore, one would reasonably expect that the dynamics of vaccine production and distribution would place a premium on incentivizing robust levels of investment in vaccine development, with the allocation of resulting vaccine occurring in ways that reflect public health priorities. Yet, that is often not the case. This book examines this disjunction from the viewpoint of the laws, policies and other market-driven forces that shape the development and distribution of vaccines. Together, these mechanisms have long led to problems of under-investment in vaccine research and production, and inequitable allocation of limited vaccine supply in ways that recurrently disadvantage lower-income populations"--
Sommario
Introduction; 1. Vaccines as instruments of public health; 2. The vaccine development ecosystem; 3. Vaccine development under proprietary paradigms; 4. Access to vaccine technology; 5. Aligning vaccine innovation with public health needs; 6. Vaccines of the future: present and emerging challenges; Conclusion: broader implications for global public health.
Info autore
Ana Santos Rutschman is outgoing Assistant Professor of law Saint Louis University and incoming Professor of Law at Villanova University. She was named a Health Law Scholar (2018) and a Bio Intellectual Property Scholar (2017) by the American Society of Law, Medicine & Ethics for her work on vaccine law and policy.
Riassunto
The COVID-19 pandemic served as a powerful wake-up call, highlighting our collective need for the effective development and equitable distribution of new vaccines, in addition to widespread administration of existing ones. The current models of production and allocation of vaccines against emerging pathogens, which rely on predominantly market-driven mechanisms, are largely at odds with public health needs. This book is the first to explore the entire arc of vaccine development and distribution, from the decisions about allocation of vaccine R&D money to allocation and administration of vaccines resulting from the R&D process. It explains key concepts and problems in vaccine regulation, intellectual property, technology transfer, and international relations, making complex material accessible to a non-specialist audience. Analyzing the impact of COVID-19, the book also covers several other vaccine races, as well as future directions in vaccine development and allocation.
Prefazione
Examines the development and allocation of vaccines against emerging diseases from the viewpoint of technology and innovation policy.
